Allogeneic engineered hematopoietic stem cell transplant lacking CD33 protein
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Allogeneic engineered hematopoietic stem cell transplant lacking CD33 protein, covering 2025-07-29 to 2025-07-29. Get the full timeline:
Most recent: Clinical Trial Update: Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS [Phase 1, Phase 2]